BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37156642)

  • 1. Agrimoniin is a dual inhibitor of AKT and ERK pathways that inhibit pancreatic cancer cell proliferation.
    Zhang X; Chen J; Xi B; Liu Y; Wang S; Gu L; Zhao H; Tao L; Hua Y; Wang Y; Chen M
    Phytother Res; 2023 Sep; 37(9):4076-4091. PubMed ID: 37156642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agrimoniin sensitizes pancreatic cancer to apoptosis through ROS-mediated energy metabolism dysfunction.
    Zhu X; Zhang Y; Wang Y; Zhang H; Wang X; Tang H; Huang H; Zhou Z; Chen B; Sun L
    Phytomedicine; 2022 Feb; 96():153807. PubMed ID: 34785107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer.
    Ding XZ; Tong WG; Adrian TE
    Oncology; 2003; 65(4):285-94. PubMed ID: 14707447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERas regulates cell proliferation and epithelial-mesenchymal transition by affecting Erk/Akt signaling pathway in pancreatic cancer.
    Liu Y; Qin P; Wu R; Du L; Li F
    Hum Cell; 2020 Oct; 33(4):1186-1196. PubMed ID: 32700262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways.
    Liu Y; Bi T; Wang G; Dai W; Wu G; Qian L; Gao Q; Shen G
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Mar; 388(3):295-304. PubMed ID: 25418891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells.
    Fujiwara M; Izuishi K; Sano T; Hossain MA; Kimura S; Masaki T; Suzuki Y
    J Exp Clin Cancer Res; 2008 Nov; 27(1):76. PubMed ID: 19032736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of AGR2 induces cell apoptosis and reduces chemotherapy resistance of pancreatic cancer cells with the involvement of ERK/AKT axis.
    Liu QG; Li YJ; Yao L
    Pancreatology; 2018 Sep; 18(6):678-688. PubMed ID: 30055941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
    Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bis(acetylacetonato)-oxidovanadium(IV) and sodium metavanadate inhibit cell proliferation via ROS-induced sustained MAPK/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells.
    Wu JX; Hong YH; Yang XG
    J Biol Inorg Chem; 2016 Dec; 21(8):919-929. PubMed ID: 27614430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y; Chen X; Luo Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
    Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
    Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways.
    Shen X; Artinyan A; Jackson D; Thomas RM; Lowy AM; Kim J
    Pancreas; 2010 Jan; 39(1):81-7. PubMed ID: 19820417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
    Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
    Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.